Skip to main content
Clinical Trials/NCT03213873
NCT03213873
Completed
Not Applicable

Effects of the HiBalance-program: Linking Clinical Signs and Symptoms to Changes in the Brain in People With Parkinson´s Disease

Karolinska Institutet1 site in 1 country95 target enrollmentAugust 15, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Karolinska Institutet
Enrollment
95
Locations
1
Primary Endpoint
Mini-BESTest
Status
Completed
Last Updated
last year

Overview

Brief Summary

This project aims to determine the effects of the HiBalance program on neuroplastic changes in people with mild to moderate Parkinson´s disease. The main hypothesis is that highly challenging exercise will lead to greater gait and balance ability, increased levels of physical activity and an improved health related quality of life. The investigators further hypothesize that neuroplasticity changes will be seen in corresponding areas of the brain, neuropsychological changes on cognitive test measures, and that exercise will inhibit the degeneration of dopaminergic neurons in the brain through the mediation of neurotrophic factors.

Detailed Description

Parkinson's disease (PD) is a neurodegenerative disease affecting many physiological systems essential for balance control. New findings suggest that intensive, challenging and cognitively demanding exercises could induce neuroplasticity in PD. A new balance training (the HiBalance program) have therefore been developed; emphasizing critical aspects of balance control through highly challenging and progressive exercises incorporating dual/multi-tasking (Conradsson et al, 2012). In an RCT, the HiBalance-program was shown to improve balance, gait and physical activity level in favor for the training group (Conradsson et al, 2015). In this proposal the investigators will combine physiotherapy, neurology and neuroimaging to characterise and determine the effects on physical and cognitive symptoms as well as structural and functional changes and wet biomarkers in the brain after the training. Participants will be recruited through Karolinska University Hospital and via announcements in relevant forums like for instance the Swedish Parkinson Association. According to earlier power calculations for detecting effects in balance and gait measures after this particular intervention, the investigators anticipate 40 to 50 participants in each group to detect significant changes. The investigators will perform both per protocol analysis and intention to treat analysis using mixed model or repeated measurement ANOVAs if the data is normally distributed.

Registry
clinicaltrials.gov
Start Date
August 15, 2017
End Date
December 23, 2019
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Erika Franzén

Associate Professor

Karolinska Institutet

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of idiopathic Parkinson´s disease
  • Hoehn \& Yahr 2-3
  • ≥ 60 years of age
  • Be able to ambulate indoors without mobility aid
  • Balance impairment

Exclusion Criteria

  • =\< 21 points on MoCA
  • Other medical conditions that could substantially influence balance performance, voice or speech performance or participation in the interventions
  • Participating in an intensive exercise program for balance or speech during the last six months.
  • Additional exclusion criteria for the brain imaging will include the presence of; pacemakers, deep brain stimulators or other MRI incompatible implants, claustrophobia, inability to hear instructions without hearing aid, unilateral or bilateral blindness, severe diplopia, tremor, dyskinesia or dystonia.

Outcomes

Primary Outcomes

Mini-BESTest

Time Frame: Pre intervention baseline and post intervention at 10 weeks

Mini-Balance Evaluation Systems Test a rating scale for dynamic balance incorporating 14 different balance and gait items that were assessed by a physical therapist on a scale from 0-2. Maximum points 28. 0-28 points with higher scores indicating better balance control

Secondary Outcomes

  • Gait Parameters(Pre intervention baseline and post intervention at 10 weeks)
  • Neuropsychological Tests(Pre intervention baseline and post intervention at 10 weeks)
  • Quality of Life Questionnaires(Pre intervention baseline and post intervention at 10 weeks)
  • Movement Disorder Society - Unified Parkinsons Disease Rating Scale (MDS-UPDRS)(Pre intervention baseline and post intervention at 10 weeks)
  • Physical Activity Measured With Accelerometers(Pre intervention baseline and post intervention at 10 weeks)
  • Structural Magnetic Resonance Imaging(Pre intervention baseline and post intervention at 10 weeks)
  • Task-induced Brain Activity as Measured by Functional Magnetic Resonance Imaging(Pre intervention baseline and post intervention at 10 weeks)
  • Wet Biomarkers(Pre intervention baseline and post intervention at 10 weeks)

Study Sites (1)

Loading locations...

Similar Trials